Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-299-8380
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.27 million
Profitability
Miscellaneous
Employees637
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) released its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($3.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($3.17) by $0.20. The biopharmaceutical company had revenue of $0.47 million for the quarter. During the same quarter last year, the company earned ($1.68) earnings per share. View SAGE Therapeutics' Earnings History.
When is SAGE Therapeutics' next earnings date?
What price target have analysts set for SAGE?
15 brokers have issued 1 year price objectives for SAGE Therapeutics' shares. Their predictions range from $80.00 to $261.00. On average, they expect SAGE Therapeutics' share price to reach $202.1538 in the next year. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.
What is the consensus analysts' recommendation for SAGE Therapeutics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.
Has SAGE Therapeutics been receiving favorable news coverage?
Media stories about SAGE stock have been trending positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. SAGE Therapeutics earned a news impact score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of SAGE Therapeutics own?
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
- Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
- Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
- Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Mr. Michael Cloonan, Chief Bus. Officer (Age 48)
Who are SAGE Therapeutics' major shareholders?
SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.87%), BlackRock Inc. (5.23%), Jennison Associates LLC (4.61%), Wellington Management Group LLP (4.32%), Janus Henderson Group PLC (3.54%) and OppenheimerFunds Inc. (2.82%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.
Which major investors are selling SAGE Therapeutics stock?
SAGE stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Oak Ridge Investments LLC, Carillon Tower Advisers Inc., Rhenman & Partners Asset Management AB, Marshall Wace LLP, Strs Ohio, Victory Capital Management Inc. and Tocqueville Asset Management L.P.. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.
Which major investors are buying SAGE Therapeutics stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, FMR LLC, TimesSquare Capital Management LLC, Artisan Partners Limited Partnership, Wellington Management Group LLP, Frontier Capital Management Co. LLC and BlackRock Inc.. View Insider Buying and Selling for SAGE Therapeutics.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $175.39.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $8.97 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.
What is SAGE Therapeutics' official website?
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
